NR2C2

Across TCGA pan-cancer cohorts, NR2C2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of NR2C2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where NR2C2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types NR2C2 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and LUAD are the cancer types where NR2C2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NR2C2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	−0.218	<.001	11	view →
PDAC	Female	II,III,IV	−0.442	<.001	9	view →
LUAD	Female	II,III,IV	−0.238	<.001	8	view →
LSCC	Male	III,IV	−0.235	<.001	8	view →
HNSC	All	All	−0.148	.001	6	view →
OV	All	All	−0.459	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

NR2C2–CCRCC

Open the CCRCC breakdown →